Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a first-in-class technology like Rani Therapeutics—whose RaniPill capsule could turn painful injections into a simple swallow—means diving into dense disclosures filled with pharmacokinetics, device engineering and trial statistics. If you’ve typed “Rani Therapeutics SEC filings explained simply” or wondered how to interpret a sudden 8-K, you already know how complex these biotech documents can be.
Stock Titan resolves that complexity in minutes, not hours. Our AI reads every Rani Therapeutics annual report 10-K simplified, flags where manufacturing risks are discussed, and delivers plain-English summaries. Need the most recent Rani Therapeutics quarterly earnings report 10-Q filing? It’s here the moment EDGAR posts. Curious about management confidence? We stream Rani Therapeutics Form 4 insider transactions real-time so you never miss a single trade. The platform also answers natural questions investors ask—“How to read Rani’s 10-K?” or “Which trial updates triggered that 8-K material events explained?”—with contextual tips embedded alongside the filings.
Use the page to:
- Monitor Rani Therapeutics insider trading Form 4 transactions and spot patterns before key catalysts.
- Compare R&D spend quarter over quarter through our Rani Therapeutics earnings report filing analysis.
- Review the Rani Therapeutics proxy statement executive compensation to understand incentive alignment.
- Quickly digest 8-K trial announcements with “understanding Rani Therapeutics SEC documents with AI” tooltips.
- Set alerts for any Rani Therapeutics executive stock transactions Form 4 filed after hours.
Whether you follow drug-delivery innovators or manage biotech risk, our real-time updates, AI-powered summaries and expert commentary transform complex filings into clear, actionable insight.
Armistice Capital, LLC and Steven Boyd disclosed ownership of 4,312,354 shares of Rani Therapeutics Holdings-A, representing 8.79% of the outstanding common stock. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over these securities while neither Armistice nor Mr. Boyd report sole voting or dispositive power.
The filing clarifies the Master Fund retains the right to receive dividends or sale proceeds, and includes a joint filing statement executed by Steven Boyd on behalf of both reporting persons.
Rani Therapeutics filed a shelf registration on Form S-3 to replace its prior registration and may offer up to $200,000,000 of Class A common stock, preferred stock, debt securities and warrants in one or more offerings. The company’s Class A common stock trades on Nasdaq under RANI (last reported sale $0.53 on August 7, 2025) and the prospectus states a public float of approximately $32.9 million based on 47,094,467 shares at $0.698 per share (July 14, 2025). The filing notes prior sales of $3.0 million under General Instruction I.B.6, making Rani currently eligible to offer up to approximately $7.9 million of Class A stock under that instruction.
Operationally, Rani is a clinical-stage biotherapeutics company developing the oral RaniPill platform. The RaniPill GO (up to 3 mg microtablets) completed three Phase 1 trials. A high-capacity RaniPill HC (up to 200 µL liquid payload) has preclinical data with antibodies and a peptide and is intended to enter clinical testing in the second half of 2025. The prospectus reiterates there are no approved products, no product revenue, and discloses forward-looking risk including concerns about the company’s ability to raise capital and substantial doubt regarding its ability to continue as a going concern.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
